Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib, Cetuximab, and Bevacizumab in Advanced Solid Tumors
NCT00101348Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, KL-140, bevacizumab in renal cell carcinoma (RCC), colorectal cancer (CRC), head and neck cancer (HNC), pancreatic cancer (PC), non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jan 2005; status: completed.
02
Drugs
erlotinibKL-140bevacizumab
03
Conditions
renal cell carcinoma (RCC)colorectal cancer (CRC)head and neck cancer (HNC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00101348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101348.